Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
122.92
-3.48 (-2.75%)
At close: Mar 28, 2025, 4:00 PM
125.00
+2.08 (1.69%)
After-hours: Mar 28, 2025, 5:42 PM EDT

Company Description

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.

The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia.

It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder.

The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc
Jazz Pharmaceuticals logo
Country Ireland
Founded 2003
IPO Date Jun 1, 2007
Industry Biotechnology
Sector Healthcare
Employees 2,800
CEO Bruce Cozadd

Contact Details

Address:
Waterloo Exchange, Fifth Floor
Dublin, D04 E5W7
Ireland
Phone 353 1 634 7800
Website jazzpharma.com

Stock Details

Ticker Symbol JAZZ
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001232524
CUSIP Number G50871105
ISIN Number IE00B4Q5ZN47
Employer ID 98-1032470
SIC Code 2834

Key Executives

Name Position
Bruce C. Cozadd Co-Founder, Chairman and Chief Executive Officer
Renee D. Gala President and Chief Operating Officer
Patricia Carr Senior Vice President and Chief Accounting Officer
Neena M. Patil J.D. Executive Vice President and Chief Legal Officer
Dr. Robert Iannone M.D. Executive Vice President, Chief Medical Officer and Global Head of Research and Development
Philip L. Johnson Executive Vice President and Chief Financial Officer
Jeff Macdonald Executive Director of Investor Relations
Kristin Bhavnani Head of Global Corporate Communications
Heidi Manna Executive Vice President and Chief People Officer
Dr. Jed Black M.D. Senior Vice President of Sleep and CNS Medicine

Latest SEC Filings

Date Type Title
Mar 10, 2025 144 Filing
Mar 10, 2025 144 Filing
Mar 7, 2025 144 Filing
Mar 7, 2025 144 Filing
Mar 7, 2025 144 Filing
Mar 5, 2025 SC TO-C Filing
Mar 5, 2025 8-K/A [Amend] Current report
Mar 5, 2025 SC TO-C Filing
Mar 5, 2025 8-K Current Report
Mar 3, 2025 144 Filing